{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:18:35Z","timestamp":1695575915767},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T00:00:00Z","timestamp":1394668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s11899-014-0202-9","type":"journal-article","created":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T07:48:50Z","timestamp":1394610530000},"page":"165-173","source":"Crossref","is-referenced-by-count":8,"title":["Novel Antibody Therapy in Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"9","author":[{"given":"Samith T.","family":"Kochuparambil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,13]]},"reference":[{"issue":"2","key":"202_CR1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"202_CR2","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","volume":"113","author":"D Pulte","year":"2009","unstructured":"Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408\u201311.","journal-title":"Blood"},{"issue":"2","key":"202_CR3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"C-H Pui","year":"2006","unstructured":"Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166\u201378.","journal-title":"N Engl J Med"},{"issue":"12","key":"202_CR4","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","volume":"106","author":"JM Rowe","year":"2005","unstructured":"Rowe JM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005;106(12):3760\u20137.","journal-title":"Blood"},{"issue":"4","key":"202_CR5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beha.2006.06.008","volume":"19","author":"N G\u00f6kbuget","year":"2006","unstructured":"G\u00f6kbuget N, Hoelzer D. Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2006;19(4):701\u201313.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"202_CR6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569\u201380.","journal-title":"Cancer"},{"key":"202_CR7","doi-asserted-by":"crossref","unstructured":"Thomas DA, Kantarjian H, Faderl S, et al. Outcome after frontline therapy with the modified hyper-CVAD regimen with or without rituximab for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) Abst 2931. In: ASH Annual Meeting; 2008.","DOI":"10.1182\/blood.V112.11.2931.2931"},{"key":"202_CR8","doi-asserted-by":"crossref","unstructured":"Rizzieri DA, Johnson J, Byrd JC, et al. Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia\/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002 Abst 858. In: ASH Annual Meeting; 2010.","DOI":"10.1182\/blood.V116.21.858.858"},{"issue":"31","key":"202_CR9","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1200\/JCO.2012.41.6768","volume":"30","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, et al. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(31):3876\u201383.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"20","key":"202_CR10","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-11-1374","volume":"71","author":"DJ FitzGerald","year":"2011","unstructured":"FitzGerald DJ, et al. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 2011;71(20):6300\u20139.","journal-title":"Cancer Res"},{"issue":"12","key":"202_CR11","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116(12):2040\u20135.","journal-title":"Blood"},{"issue":"10","key":"202_CR12","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","volume":"28","author":"T Robak","year":"2010","unstructured":"Robak T, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756\u201365.","journal-title":"J Clin Oncol"},{"issue":"10","key":"202_CR13","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","volume":"112","author":"MN Dworzak","year":"2008","unstructured":"Dworzak MN, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112(10):3982\u20138.","journal-title":"Blood"},{"issue":"24","key":"202_CR14","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","volume":"28","author":"DA Thomas","year":"2010","unstructured":"Thomas DA, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"202_CR15","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","volume":"28","author":"WG Wierda","year":"2010","unstructured":"Wierda WG, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749\u201355.","journal-title":"J Clin Oncol"},{"key":"202_CR16","doi-asserted-by":"crossref","unstructured":"Jabbour E, Hagop K, O\u2019Brien S. Phase II study of the Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL) Abst 2664. In: ASH Annual Meeting; 2013.","DOI":"10.1200\/jco.2014.32.15_suppl.7065"},{"issue":"3","key":"202_CR17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","volume":"136","author":"D Nagorsen","year":"2012","unstructured":"Nagorsen D, et al. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136(3):334\u201342.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"202_CR18","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","volume":"106","author":"R Tibes","year":"2006","unstructured":"Tibes R, Keating MJ, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106(12):2645\u201351.","journal-title":"Cancer"},{"issue":"5891","key":"202_CR19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974\u20137.","journal-title":"Science"},{"issue":"26","key":"202_CR20","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","volume":"120","author":"MS Topp","year":"2012","unstructured":"Topp MS, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185\u20137.","journal-title":"Blood"},{"key":"202_CR21","doi-asserted-by":"crossref","unstructured":"Topp MS, Goekbuget N, Zugmaier G. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia (ALL) Abst 670. In: ASH Annual Meeting; 2012.","DOI":"10.1182\/blood.V120.21.670.670"},{"issue":"10","key":"202_CR22","first-page":"3982S","volume":"9","author":"J Carnahan","year":"2003","unstructured":"Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9(10):3982S\u201390.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"202_CR23","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","volume":"21","author":"JP Leonard","year":"2003","unstructured":"Leonard JP, et al. Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2003;21(16):3051\u20139.","journal-title":"J Clin Oncol"},{"issue":"22","key":"202_CR24","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","volume":"26","author":"EA Raetz","year":"2008","unstructured":"Raetz EA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a children\u2019s oncology group pilot study. J Clin Oncol. 2008;26(22):3756\u201362.","journal-title":"J Clin Oncol"},{"key":"202_CR25","doi-asserted-by":"crossref","unstructured":"Raetz AE, Cairo M, Borowitz MJ, et al. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children\u2019s Oncology Group (COG) study ADVL04P2. Abst 573. In: ASH Annual Meeting; 2011.","DOI":"10.1182\/blood.V118.21.573.573"},{"key":"202_CR26","doi-asserted-by":"crossref","unstructured":"Advani A, McDonough S, Coutre S, et al. Southwest Oncology Group study S0910: a phase 2 trial of clofarabine\/ cytarabine\/ epratuzumab for relapsed\/ refractory acute lymphocytic leukemia, Abs#2603. In: ASH Annual Meeting; 2012.","DOI":"10.1182\/blood.V120.21.2603.2603"},{"issue":"10","key":"202_CR27","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554\u201361.","journal-title":"Blood"},{"issue":"4","key":"202_CR28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood.V85.4.1122.bloodjournal8541122","volume":"85","author":"D Matthews","year":"1995","unstructured":"Matthews D, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995;85(4):1122\u201331.","journal-title":"Blood"},{"key":"202_CR29","doi-asserted-by":"crossref","unstructured":"Lozanski G, et al. Quantitative measurement of CD52 expression and alemtuzumab binding in adult acute lymphoblastic leukemia (ALL) Abst:2386. In: ASH Annual conference; 2007.","DOI":"10.1182\/blood.V110.11.2386.2386"},{"key":"202_CR30","doi-asserted-by":"crossref","unstructured":"Stock W, Sanford S. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102) Abst 838. In: ASH Annual Meeting; 2009.","DOI":"10.1182\/blood.V114.22.838.838"},{"issue":"12","key":"202_CR31","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1080\/10428190701647879","volume":"48","author":"RI Cruz","year":"2007","unstructured":"Cruz RI, et al. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma. 2007;48(12):2424\u201336.","journal-title":"Leuk Lymphoma"},{"key":"202_CR32","doi-asserted-by":"crossref","unstructured":"Thorson JS, Sievers EL, Ahlert J, et al. Understanding and exploiting natures chemical arsenal: the past, present and future of calicheamicin research; 2000","DOI":"10.2174\/1381612003398564"},{"issue":"12","key":"202_CR33","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","volume":"28","author":"A Advani","year":"2010","unstructured":"Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085\u201393.","journal-title":"J Clin Oncol"},{"issue":"4","key":"202_CR34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","volume":"13","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22\u2013calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403\u201311.","journal-title":"Lancet Oncol"},{"issue":"3","key":"202_CR35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2012.12.003","volume":"13","author":"P Kebriaei","year":"2013","unstructured":"Kebriaei P, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13(3):296\u2013301.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"202_CR36","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Thomas D, Jorgensen JL, et al. Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL) Abst 671. In: ASH Annual Meeting; 2012.","DOI":"10.1182\/blood.V120.21.671.671"},{"issue":"15","key":"202_CR37","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","volume":"119","author":"H Kantarjian","year":"2013","unstructured":"Kantarjian H, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728\u201336.","journal-title":"Cancer"},{"issue":"20","key":"202_CR38","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","volume":"17","author":"RJ Kreitman","year":"2011","unstructured":"Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17(20):6398\u2013405.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"202_CR39","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-09-2980","volume":"16","author":"AS Wayne","year":"2010","unstructured":"Wayne AS, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010;16(6):1894\u2013903.","journal-title":"Clin Cancer Res"},{"key":"202_CR40","doi-asserted-by":"crossref","unstructured":"Wayne AS, Bhojwani D, Silverman LB, et al. Novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia. Abst 248. In: ASH Annual Meeting; 2011.","DOI":"10.1182\/blood.V118.21.248.248"},{"issue":"12","key":"202_CR41","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/MPH.0b013e3181bdf211","volume":"31","author":"L Herrera","year":"2009","unstructured":"Herrera L, et al. A phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2009;31(12):936\u201341. doi: 10.1097\/MPH.0b013e3181bdf211 .","journal-title":"J Pediatr Hematol Oncol"},{"key":"202_CR42","doi-asserted-by":"crossref","unstructured":"Chevallier P, Bodet-Milin C, Robillard N, Eugene T, Kraeber-Bodere F. BCR-ABL1 molecular remission after 90y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph + B-ALL: a potential new treatment paradigm. Abst 3910. In: ASH Annual Meeting; 2013.","DOI":"10.1111\/ejh.12183"},{"key":"202_CR43","unstructured":"Park JH, Brentjens R. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med. 2010."},{"issue":"6","key":"202_CR44","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.hoc.2011.09.015","volume":"25","author":"JH Park","year":"2011","unstructured":"Park JH, Sauter C, Brentjens R. Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin N Am. 2011;25(6):1281\u2013301.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"177","key":"202_CR45","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, et al. CD19-targeted t cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.","journal-title":"Sci Transl Med"},{"issue":"16","key":"202_CR46","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med"},{"key":"202_CR47","unstructured":"Grupp SA, Frey NV, et al. Acute lymphoblastic leukemia: therapy, excluding transplantation: novel immune-based therapies and novel targets Abst 67. In: ASH Annual Conference; 2013."},{"key":"202_CR48","doi-asserted-by":"crossref","unstructured":"Lee DW III, Shah NN, et al. Anti-CD19 Chimeric Antigen Receptor (CAR) T cells produce complete responses with acceptable toxicity but without chronic B-cell aplasia in children with relapsed or refractory acute lymphoblastic leukemia (ALL) even after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Abst 68. In: ASH Annual Meeting; 2013. Emerging Therapy CAR.","DOI":"10.1182\/blood.V122.21.68.68"},{"key":"202_CR49","unstructured":"Davila ML, Riviere I, Wang X, et al. Acute lymphoblastic leukemia: therapy, excluding transplantation: novel immune-based therapies and novel targets Abst 69. In: ASH Annual Meeting; 2013. Emerging Therapy CAR."},{"issue":"7","key":"202_CR50","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso W, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165\u201374.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-014-0202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-014-0202-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-014-0202-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T07:06:36Z","timestamp":1597561596000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-014-0202-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,13]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1007\/s11899-014-0202-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,13]]}}}